HomeNewsBusinessCompaniesE-pharmacy firm 1mg says investing in cold chain, training staff for COVID-19 vaccination
Trending Topics

E-pharmacy firm 1mg says investing in cold chain, training staff for COVID-19 vaccination

Prashant Tandon, chief of the e-pharmacy firm told Moneycontrol that 1mg is keen to participate in the COVID vaccination drive but is awaiting clarity on when and how the private sector can participate

February 09, 2021 / 18:51 IST
Story continues below Advertisement
Prashant Tandon, CEO, 1mg
Prashant Tandon, CEO, 1mg

India's leading e-pharmacy company 1mg said it is investing in expansion of its cold chain, training thousands of vaccinators and is in touch with vaccine makers for possible partnerships to participate in COVID-19 vaccination, as and when the government allows the private sector.

"We are waiting to get some clarity from the government as to when and how the private sector can participate, at 1mg we are keen to participate," said Prashant Tandon, CEO of 1mg to Moneycontrol.

Story continues below Advertisement

Tandon said 1mg has put in place four key things like information about the vaccine, administration, supply chain and doctor consultation for successful rollout COVID-19 vaccination.

"We do vaccinations for flu shots, pneumococcal vaccine and hepatitis-B, we have the expertise, so what we are doing now is we are investing in setting up a cold chain for vaccine supplies, currently we have 500 trained technicians who can administer the vaccine, we are training network of 5,000 to 10,000 vaccinators, we are in touch with a bunch of vaccine manufacturers for possible tie-ups," Tandon said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show